✦ LIBER ✦

WS1.1 The effect of ivacaftor, a CFTR potentiator, in patients with cystic fibrosis and a non-G551D-CFTR gating mutation, the KONNECTION study

✍ Scribed by De Boeck, K.; Munck, A.; Walker, S.; Faro, A.; Hiatt, P.; Chan, J.; Gilmartin, G.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

WS6.5 Ivacaftor in subjects 6 to 11 year

✍ J.C. Davies; H. Li; K. Yen; R. Ahrens 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

WS3.1 The effect of ivacaftor on the rat

✍ Sawicki, G.S.; McKone, E.; Pasta, D.J.; Wagener, J.; Johnson, C.; Konstan, M.W. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 67 KB

WS6.4 Long-term safety and efficacy of i

✍ E. McKone; H. Li; K. Yen; J.C. Davies 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB

WS23.3 ICM is sensitive to detect potent

✍ Graeber, S.Y.; Hug, M.J.; Sommerburg, O.; Mainz, J.G.; Heinzmann, A.; Tümmler, B 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A CFTR corrector (lumacaftor) and a CFTR

✍ Boyle, Michael P; Bell, Scott C; Konstan, Michael W; McColley, Susanna A; Rowe, 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 423 KB

44 Pulmonary exacerbations in a Phase 3

✍ M. Griese; B. Ramsey; S. Rodriguez; K. Yen; J.S. Elborn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB